Skip to content

EV / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
3.3×-0.1×
Amgen logo
AmgenAMGN
6.6×+0.1×
Tango Therapeutics logo
Tango TherapeuticsTNGX
50.1×+47.1×
Arcus Biosciences logo
Arcus BiosciencesRCUS
11.1×+6.1×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
150.4×+98.6×
Summit Therapeutics logo
Summit TherapeuticsSMMT
8,448.1×+8,132×

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: IDEAYA Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s EV / sales?
IDEAYA Biosciences, Inc. (IDYA) reported EV / sales of 308× in Q4 2024.
How has IDEAYA Biosciences, Inc.'s EV / sales changed year-over-year?
IDEAYA Biosciences, Inc.'s EV / sales increased by 232.3% year-over-year, from 92.7× to 308×.
What is the long-term trend for IDEAYA Biosciences, Inc.'s EV / sales?
Over 3 years (2021 to 2024), IDEAYA Biosciences, Inc.'s EV / sales has grown at a 118.7% compound annual growth rate (CAGR), from 29.5× to 308×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.